Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -24.64% is 44% above its 5-year average of -44.33%, near the high end of its 5-year range (-64.05%–-24.64%).
46.41% above its 12-month average of -45.98%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -6.78%.
RETURN ON ASSETS (ROA)
-24.64%
RETURN ON ASSETS (ROA) AVG TTM
-45.98%
RETURN ON ASSETS (ROA) AVG 3Y
-40.55%
RETURN ON ASSETS (ROA) AVG 5Y
-44.33%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+46.41%
CURRENT VS 3Y AVG
+39.23%
CURRENT VS 5Y AVG
+44.42%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-28.14%
median of 562 covered companies
CURRENT VS SECTOR MEDIAN
+12.45%
vs the sector median at left
Artiva Biotherapeutics, Inc.
Market Cap
$340.28M
Return on Assets (ROA)
-24.64%
TTM Avg
-45.98%
3Y Avg
-40.55%
5Y Avg
-44.33%
Market Cap
$337.38M
Return on Assets (ROA)
-39.85%
TTM Avg
-37.20%
3Y Avg
-38.95%
5Y Avg
-33.46%
Market Cap
$342.72M
Return on Assets (ROA)
53.28%
TTM Avg
-50.19%
3Y Avg
-57.97%
5Y Avg
-53.56%
Market Cap
$326.11M
Return on Assets (ROA)
-70.63%
TTM Avg
-82.15%
3Y Avg
-59.06%
5Y Avg
-50.33%
Market Cap
$353.30M
Return on Assets (ROA)
6.92%
TTM Avg
7.42%
3Y Avg
10.30%
5Y Avg
25.30%
Market Cap
$325.07M
Return on Assets (ROA)
-28.22%
TTM Avg
-29.68%
3Y Avg
-31.08%
5Y Avg
-26.24%
Market Cap
$352.72M
Return on Assets (ROA)
-21.30%
TTM Avg
-29.99%
3Y Avg
-30.23%
5Y Avg
-24.37%
Market Cap
$357.79M
Return on Assets (ROA)
-4.29%
TTM Avg
-7.44%
3Y Avg
-40.66%
5Y Avg
-49.61%
Market Cap
$354.62M
Return on Assets (ROA)
-115.75%
TTM Avg
-127.38%
3Y Avg
-59.19%
5Y Avg
-98.90%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | $340.28M | -24.64% | -45.98% | -40.55% | -44.33% |
| ClearPoint Neuro, Inc. (CLPT)vs › | $337.38M | -39.85% | -37.20% | -38.95% | -33.46% |
| Agenus Inc. (AGEN)vs › | $342.72M | 53.28% | -50.19% | -57.97% | -53.56% |
| Cabaletta Bio, Inc. (CABA)vs › | $326.11M | -70.63% | -82.15% | -59.06% | -50.33% |
| Embecta Corp. (EMBC)vs › | $353.30M | 6.92% | 7.42% | 10.30% | 25.30% |
| C4 Therapeutics, Inc. (CCCC)vs › | $325.07M | -28.22% | -29.68% | -31.08% | -26.24% |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $352.72M | -21.30% | -29.99% | -30.23% | -24.37% |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $357.79M | -4.29% | -7.44% | -40.66% | -49.61% |
| Opus Genetics, Inc. (IRD)vs › | $354.62M | -115.75% | -127.38% | -59.19% | -98.90% |
| CapsoVision, Inc. (CV)vs › | $322.44M | -160.64% | -128.90% | -103.44% | -103.44% |
ROA
-24.6%
ROE
-26.1%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -64.05% |
| 2024-12-31 | -27.91% |
| 2023-12-31 | -26.35% |
| 2022-12-31 | -43.88% |
| 2021-12-31 | -42.27% |
| 2020-12-31 | -61.54% |
| 2019-12-31 | 0.00% |
